You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

induction immunotherapy and chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nasopharyngeal Carcinoma Trial in Fuzhou (without concurrent cisplatin chemo, with concurrent cisplatin chemo)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • without concurrent cisplatin chemotherapy
  • with concurrent cisplatin chemotherapy
  • Fuzhou, Fujian, China
    Department of radiation oncology, Fujian cancer hospital
Oct 18, 2023

Cervical Cancer, Induction Chemo, Immunotherapy Trial in Tianjin (Toripalimab)

Recruiting
  • Cervical Cancer
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Oct 16, 2023

Colon Tumor Trial in Hangzhou (Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody)

Not yet recruiting
  • Colon Neoplasm
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital of Zhejiang University School of Medi
Jun 25, 2023

Lung Cancer, Non-small Cell Trial in Nanjing (hypofractionated radiation therapy)

Active, not recruiting
  • Lung Cancer, Non-small Cell
  • hypofractionated radiation therapy
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Mar 13, 2023

Head Neck Cancer Trial in Beijin (anti-PD-1 or PD-L1 antibody, postoperative radiaotherapy)

Recruiting
  • Head and Neck Cancer
  • anti-PD-1 or PD-L1 antibody
  • postoperative radiaotherapy
  • Beijin, Beijing, China
    National Cancer Center /National Clinical Research Center for Ca
Mar 18, 2023

Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemo)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Split-course hypo-CCRT
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Aug 26, 2023

Chemo, Radiation Therapy Trial in Fuzhou (Camrelizumab, Paclitaxel, Cisplatin)

Not yet recruiting
  • Chemotherapy
  • Radiation Therapy
  • Fuzhou, China
    Fujian Medical University Union Hospital
Apr 6, 2023

NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage III
  • radiotherapy
  • +3 more
  • (no location specified)
Sep 10, 2023

Nasopharyngeal Carcinoma, De-escalation Therapy Trial in Guangzhou (Cisplatin-based induction chemo, Full course of PD-1/PD-L1

Recruiting
  • Nasopharyngeal Carcinoma
  • De-escalation Therapy
  • Cisplatin-based induction chemotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 16, 2023

Nasopharyngeal Carcinoma, De-escaltion Therapy Trial in Guangzhou (Reduced-target resection, Full-target resection, Adjuvant

Recruiting
  • Nasopharyngeal Carcinoma
  • De-escaltion Therapy
  • Reduced-target resection
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 25, 2023

Immunotherapy Esophagus Cancer Trial (Tislelizumab, Albumin paclitaxel, Nedaplatin)

Not yet recruiting
  • Immunotherapy Esophagus Cancer
  • (no location specified)
Aug 24, 2022

Hypopharyngeal Carcinoma, Immunotherapy, Chemo Trial in Shanghai (Docetaxel, Cisplatin, Capecitabine)

Recruiting
  • Hypopharyngeal Carcinoma
  • +2 more
  • Shanghai, Shanghai, China
    Eye & ENT Hospital, Fudan University
Dec 1, 2021

NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)

Recruiting
  • Non-small Cell Lung Cancer
  • Hypofractionated radiotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun yat-sen university cancer center
Nov 14, 2023

Breast Cancer, Breast Tumors Trial in Portland (Pembrolizumab, IRX 2)

Recruiting
  • Breast Cancer
  • Breast Neoplasms
  • Portland, Oregon
    Providence Portland Medical Center
Jan 31, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Immunotherapy+induction chemo+radiotherapy)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Immunotherapy+induction chemotherapy+radiotherapy
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 9, 2022

Hypopharyngeal Cancer, Immunotherapy, Induction Chemo Trial in Guangzhou (Camrelizumab)

Recruiting
  • Hypopharyngeal Cancer
  • +2 more
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Aug 14, 2021

NSCLC, Stage III Trial in Germany (Durvalumab)

Recruiting
  • NSCLC, Stage III
  • Essen, Germany
  • +3 more
Aug 27, 2021

Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy Trial in Wuhan (CTV omitted or delineated)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • CTV omitted or delineated
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Sep 1, 2023

Metastatic NSCLC Trial in France (Pembrolizumab before randomization, Chemotherapy, Pemetrexed)

Recruiting
  • Metastatic NSCLC
  • Pembrolizumab before randomization
  • +3 more
  • Aix-en-Provence, France
  • +37 more
Jul 26, 2022

Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy Trial in Wuhan (CTV omitted or delineated)

Not yet recruiting
  • Advanced Non-Small Cell Squamous Lung Cancer
  • +2 more
  • CTV omitted or delineated
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Sep 7, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in New York (haplo-identical cells (donor), umbilical cord blood unit

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • haplo-identical cells (donor)
  • umbilical cord blood unit (CBU)
  • New York, New York
    Weill Cornell Medical College
Dec 14, 2022

NSCLC Trial in Changsha (Sugemalimab and Chemotherapy)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sugemalimab and Chemotherapy
  • Changsha, China
    Hunan Cancer Hospital
Jul 7, 2023

Non Small Cell Lung Cancer Trial in Wuhan (Carrelizumab, Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC),

Recruiting
  • Non Small Cell Lung Cancer
  • Wuhan, China
    Wuhan Union Hospital
Aug 27, 2021

Small Cell Lung Carcinoma Trial in Milano (Cyclic, 5-day calorie restriction, Atezolizumab)

Not yet recruiting
  • Small Cell Lung Carcinoma
  • Milano, Italy
    Fondazione IRCCS Istituto Nazionale Tumori
Jan 19, 2023

Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy Trial (chemo combined with PD-1 inhibitors)

Not yet recruiting
  • Esophageal Squamous Cell Carcinomas
  • +3 more
  • chemotherapy combined with PD-1 inhibitors
  • (no location specified)
Nov 17, 2022